- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
More ▼
Key statistics
On Friday, Arbutus Biopharma Corp (I9DN:FRA) closed at 2.99, -2.98% below its 52-week high of 3.09, set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.99 |
---|---|
High | 2.99 |
Low | 2.99 |
Bid | 3.07 |
Offer | 3.12 |
Previous close | 3.01 |
Average volume | 966.30 |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 634.09m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:07 BST.
More ▼